Port-a-cath OcclusionNCT05707936
Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath
A study testing Normal Saline Flush 20 ml, Normal Saline Flush 10 ml and Heparin Flush (1000 USP, 10ml) in people with Port-a-cath Occlusion and Normal Saline, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
Purpose: An evidence implementation of a randomized controlled trial for whether there is the difference in intermittent flushing 0.9% normal saline and heparin? Design: a single-blind randomized controlled trial Method: This study is based on the 5A (Ask, Acquire, Appraise, Apply, Audit) of evidence health care step… Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Port-a-cath Occlusion, Normal Saline, Heparin Lock
- What is being tested?
- Normal Saline Flush 20 ml, Normal Saline Flush 10 ml and Heparin Flush (1000 USP, 10ml)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 192 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Feb 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Non-pediatric inpatients over 20 years of age with PAC placed for any disease and who need medication during hospitalization.
Who cannot join
- History of PAC obstruction, continuous high volume drip via PAC, taking anticoagulant or antiplatelet agents, abnormal blood coagulation, pregnancy or contraceptive use, specified flushing solution by case
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath: Randomized Controlled Trial
Purpose:
An evidence implementation of a randomized controlled trial for whether there is the difference in intermittent flushing 0.9% normal saline and heparin? Design: a single-blind randomized controlled trial
Read more
Method:
This study is based on the 5A (Ask, Acquire, Appraise, Apply, Audit) of evidence health care step, and design randomized controlled trial for evidence implementation.
We will include inpatients over 20 years-old adults in New Taipei City TuCheng Hospital, Taiwan, who need administration medicine by port-a-catcher. The sample size is 192 according to G-power software. Random allocation software has using for block randomization, would assign to group A: flushing with 0.9% normal saline 10ml, group B: flushing with 0.9% normal saline 20ml, and group C: flushing with heparin 100 USP/ml. SPSS 20.0 software for statistical analysis, mean or standard deviation, one- way ANOVA would use.
- Conditions
- Port-a-cath Occlusion, Normal Saline, Heparin Lock
- Being tested
- Normal Saline Flush 20 ml, Normal Saline Flush 10 ml, Heparin Flush (1000 USP, 10ml)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Normal Saline Flush 20 mlDrug
Normal Saline Flush 20 ml
Normal Saline Flush 10 mlDrug
Normal Saline Flush 10 ml
Heparin Flush (1000 USP, 10ml)Drug
Heparin Flush (1000 USP, 10ml)
| Study group | Role | What they receive |
|---|---|---|
| Normal saline 20 ml | Experimental | Not described Receives: Drug: Normal Saline Flush 20 ml |
| Normal saline 10 ml | Experimental | Not described Receives: Drug: Normal Saline Flush 10 ml |
| usual care (heparin) | Active comparator | Not described Receives: Drug: Heparin Flush (1000 USP, 10ml) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with TIVAD (Port-a-Cath) occlusion
failure to infusion fluid
Measured: From enrollment until 30 days after enrollment or TIVAD discontinuation, whichever occurred first (up to 30 days).
Number of participants with catheter-related bloodstream infection (CRBSI)
CRBSI was defined according to the Taiwan Centers for Disease Control criteria.
Measured: From enrollment until 30 days after enrollment or TIVAD discontinuation, whichever occurred first (up to 30 days).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2023
- Study start1 Feb 2023
- Primary completion19 Oct 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Port-a-cath OcclusionStudies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 192 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05707936
- Sponsor's protocol ID
- CMRPVVM0141
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2022
- Last updated
- 21 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ho CJ, Hsieh JC, Xu HG, Yen CC, Kuo HC, Chou CT, Chen LC, Wang BC. Flushing Strategies for Totally Implantable Venous Access Devices in Nurse-Led Cancer Care: Exploratory Randomized Clinical Trial. Nurs Open. 2026 Oct;13(10):e70942. doi: 10.1002/nop2.70942.
PubMed 42888507
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05707936
- Acronym / sponsor ID
- CMRPVVM0141
- Conditions
- Port-a-cath Occlusion, Normal Saline, Heparin Lock
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 192 participants (actual)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Study start
- 1 Feb 2023 (actual)
- Primary completion
- 19 Oct 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 1 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose:
An evidence implementation of a randomized controlled trial for whether there is the difference in intermittent flushing 0.9% normal saline and heparin? Design: a single-blind randomized controlled trial
Method:
This study is based on the 5A (Ask, Acquire, Appraise, Apply, Audit) of evidence health care step, and design randomized controlled trial for evidence implementation.
We will include inpatients over 20 years-old adults in New Taipei City TuCheng Hospital, Taiwan, who need administration medicine by port-a-catcher. The sample size is 192 according to G-power software. Random allocation software has using for block randomization, would assign to group A: flushing with 0.9% normal saline 10ml, group B: flushing with 0.9% normal saline 20ml, and group C: flushing with heparin 100 USP/ml. SPSS 20.0 software for statistical analysis, mean or standard deviation, one- way ANOVA would use.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Normal saline 20 ml | Experimental | Drug: Normal Saline Flush 20 ml |
| Normal saline 10 ml | Experimental | Drug: Normal Saline Flush 10 ml |
| usual care (heparin) | Active comparator | Drug: Heparin Flush (1000 USP, 10ml) |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Non-pediatric inpatients over 20 years of age with PAC placed for any disease and who need medication during hospitalization.
Key exclusion criteria (1 listed)
- History of PAC obstruction, continuous high volume drip via PAC, taking anticoagulant or antiplatelet agents, abnormal blood coagulation, pregnancy or contraceptive use, specified flushing solution by case
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Normal Saline Flush 20 mlNormal Saline Flush 20 ml | Drug | Normal saline 20 ml |
| Normal Saline Flush 10 mlNormal Saline Flush 10 ml | Drug | Normal saline 10 ml |
| Heparin Flush (1000 USP, 10ml)Heparin Flush (1000 USP, 10ml) | Drug | usual care (heparin) |
Primary outcome
Number of participants with TIVAD (Port-a-Cath) occlusion
Time frame: From enrollment until 30 days after enrollment or TIVAD discontinuation, whichever occurred first (up to 30 days).
failure to infusion fluid
Number of participants with catheter-related bloodstream infection (CRBSI)
Time frame: From enrollment until 30 days after enrollment or TIVAD discontinuation, whichever occurred first (up to 30 days).
CRBSI was defined according to the Taiwan Centers for Disease Control criteria.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Derived from this study: PubMed 42888507Ho CJ, Hsieh JC, Xu HG, Yen CC, Kuo HC, Chou CT, Chen LC, Wang BC. Flushing Strategies for Totally Implantable Venous Access Devices in Nurse-Led Cancer Care: Exploratory Randomized Clinical Trial. Nurs Open. 2026 Oct;13(10):e70942. doi: 10.1002/nop2.70942.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Normal Saline Flush 20 ml, Normal Saline Flush 10 ml and Heparin Flush (1000 USP, 10ml) in people with Port-a-cath Occlusion and Normal Saline, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with TIVAD (Port-a-Cath) occlusion (time frame: From enrollment until 30 days after enrollment or TIVAD discontinuation, whichever occurred first (up to 30 days).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05707936, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.